ERBB2 and breast carcinoma: Another study reported development of doxorubicin-loaded liposomes modified with a lipid stearic acid-peptidomimetic conjugate, aiming to ensure targeted delivery in non-small-cell lung cancer and breast cancer cell lines overexpressing human epidermal growth factor receptor-2 (HER2) [43].